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Abstract
Many recent imaging genetic studies focus on detecting the associations between genetic markers 
such as single nucleotide polymorphisms (SNPs) and quantitative traits (QTs). Although there 
exist a large number of generalized multivariate regression analysis methods, few of them have 
used diagnosis information in subjects to enhance the analysis performance. In addition, few of 
models have investigated the identification of multi-modality phenotypic patterns associated with 
interesting genotype groups in traditional methods. To reveal disease-relevant imaging genetic 
associations, we propose a novel diagnosis-guided multi-modality (DGMM) framework to 
discover multi-modality imaging QTs that are associated with both Alzheimer's disease (AD) and 
its top genetic risk factor (i.e., APOE SNP rs429358). The strength of our proposed method is that 
it explicitly models the priori diagnosis information among subjects in the objective function for 
selecting the disease-relevant and robust multi-modality QTs associated with the SNP. We 
evaluate our method on two modalities of imaging phenotypes, i.e., those extracted from structural 
magnetic resonance imaging (MRI) data and fluorodeoxyglucose positron emission tomography 
(FDG-PET) data in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The 
experimental results demonstrate that our proposed method not only achieves better performances 
under the metrics of root mean squared error and correlation coefficient but also can identify 
common informative regions of interests (ROIs) across multiple modalities to guide the disease-
induced biological interpretation, compared with other reference methods.
1. Introduction
Neuroimaging genetics emerges as one of the hottest research topics in recent studies, which 
identifies genetic variant associations with imaging phenotypes such as structural or 
functional imaging measures. Since neuroimaging plays an important role in characterizing 
the neurodegenerative process of many brain disease such as Alzheimer's disease (AD) [1], 
the quantitative imaging phenotypes can provide valuable information so that it holds great 
promise for revealing the complex biological mechanisms of the disease.
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Genome-wide association studies (GWAS) have been widely used to identify the 
associations between single nucleotide polymorphisms (SNPs) and the quantitative traits 
(QTs) such as neuroimaging measures. To address the high dimensionality of the GWAS 
data and small effect size of individual SNPs, in recent imaging genetic studies, researchers 
have developed several generalized multivariate linear regression analysis methods by 
considering the priori knowledge such as inherent structural information to boost the 
detection power [2, 3]. Although those methods may have the potential to help discover 
phenotypic imaging markers related to some candidate risk SNPs [4], another problem of 
existing methods in imaging genetics is that the subjects' diagnosis information (e.g., class 
labels such as patients or healthy controls) is not fully used for revealing disease-specific 
imaging genetic associations. More recently, some diagnosis induced methods have been 
proposed to solve the imaging genetics problem [5, 6]. A two-step strategy was adopted by 
[5]: 1) initially, the authors identified the voxels that could provide an imaging signature of 
the disease with high classification accuracy using penalized linear discriminant analysis; 2) 
then they detected the SNPs associated with the multivariate phenotypic markers discovered 
in the first step. Moreover, a Bayesian framework for detecting genetic variants associated 
with a disease while exploiting imaging as an intermediate phenotype was proposed in [6], 
which was designed to jointly identify relevant imaging and genetic markers simultaneously. 
In addition, most of imaging genetic studies focus on discovering the associations between 
single imaging modality (e.g., magnetic resonance imaging (MRI)) and SNPs, while 
ignoring the underlying interacting relationships among multiple modalities.
With these observations, our general motivation is to identify multimodal imaging 
phenotypes serving as intermediate traits between a given AD genetic marker and disease 
status, where we hope to design a simple and powerful model to maximize disease-relevant 
imaging genetic associations. Accordingly, the ideas introduced in [7, 8] can be adopted and 
incorporated into the imaging genetics studies. Specifically in [7, 8], subjects' similarity has 
been successfully used for designing more powerful multi-modal models on AD 
classification and clinical score regression solutions, which are inspired by multi-task 
modeling integrated with the priori relationship between sample data and the corresponding 
labels in machine learning community [9].
In this study, we propose a novel diagnosis-guided multi-modality (DGMM) framework that 
considers robust and common regions of interests (ROIs) as well as diagnosis labels such as 
patients or healthy controls to handle the multi-modality phenotype associations with an AD 
genetic risk factor. We evaluate our DGMM method on two modalities of phenotypes, i.e., 
voxel-based measures extracted from structural MRI and fluorodeoxyglucose positron 
emission tomography (FDG-PET)) scans, as well as apolipoprotein E (APOE) SNP 
rs429358 (the best known AD genetic risk factor [10, 11]) data from the Alzheimer's 
Disease Neuroimaging Initiative (ADNI) cohort. The empirical results show that our method 
not only yield improved performances under the metrics of correlation coefficient and root 
mean squared error, but also detect a compact set of consistent and robust ROIs across two 
imaging modalities which are relevant to the studied genetic risk marker.
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2. Method
2.1. Genotype and Phenotype Association
In this section, we systematically develop our computational models to explore the 
association between a candidate AD risk SNP and multimodal imaging phenotypes. That is, 
our proposed method mainly addresses the problem based on the general linear (least 
square) regression approach. Given imaging phenotypes X = [x1, …, xn, …, xN]T ∈ RN×d as 
input and a candidate risk SNP y = [y1, …, yn, …, yN]T ∈ RN as output in the regression 
model, where N is the number of participants (sample size) and d is the number of imaging 
phenotype ROIs (feature dimensionality). The association model is designed to solve:
(1)
where R(w) is a regularization term and λ is the corresponding parameter. The weight vector 
w measures the relative importance of the imaging phenotypes (i.e., ROI measures) in 
predicting the response of the SNP.
In the work, the goal of the learned regression model is not to discover relevant SNPs, but to 
select biologically meaningful imaging phenotypes that are associated jointly with a given 
risk SNP and the disease status. Using the linear general regression model formulated by Eq 
(1), we aim to identify interesting imaging phenotypes that can serve as intermediate traits 
on the pathway from an AD genetic risk factor to the clinical diagnosis.
2.2. Diagnosis-Guided Single-modality Phenotype Association
In this study, we consider the relationship between imaging phenotypes and the diagnosis 
information among subjects which are not fully used in conventional association analysis 
methods. More specifically, we will utilize the relationship information among subjects with 
diagnosis labels, i.e., AD, mild cognitive impairment (MCI) or healthy controls (HC). That 
is, if subjects are similar to each other in the original diagnosis feature space, their respective 
response values should be also similar. To solve this problem, we induce a new 
regularization term that can preserve the class level diagnosis information:
(2)
where S = [Sij] ∈ Rn×n denotes a similarity matrix that measures the similarity between 
every pair of samples. L = D − S represents a Laplacian matrix, where D is the diagonal 
matrix with element defined as . Then, the similarity matrix can be defined as:
(3)
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The penalized term Eq. (2) enforces that, after being mapped into the label space, the 
distance between the within-class data will be small, which preserves the local neighborhood 
structure of the same class. We induce the diagnosis labels constraint into the single 
modality phenotypic solution and then formulate a diagnosis-guided single modality 
(DGSM) phenotype association model as follows:
(4)
The strength of DGSM method is that it explicitly models the priori diagnosis information 
among subjects in the objective function that minimize distance within each diagnosis class 
for selecting the disease-relevant QT associated with the SNP. Especially, the DGSM model 
can generalize and handle the progressive disease with multi-diagnosis status, comparing to 
the binary diagnosis analysis methods that were adopted in [5, 6].
2.3. Multi-modality Phenotype Associations
We assume that there are N training subjects or samples, with each represented by M 
modalities of phenotypes. Denote  as the data matrix 
of the m -th modality, and Y = [Y1, …, Y2, …, Yn]T ∈ RN be the corresponding response 
values (i.e. APOE SNP rs429358). Let wm ∈ Rd be the linear discriminant function 
corresponding to the m-th modality. Then the multi-modality phenotype association model 
can be formulated as follows:
(5)
where W = [w1, w2, …, wM] ∈ Rd×M is the weight matrix whose row wj is the vector of 
coefficients assigned to the j-th feature across different modalities, and 
 is penalize all coefficients in the same row of matrix W for joint 
feature selection. First, the l2,1-norm regularization term is a “group-sparsity” regularizer, 
which forces only a small number of features being selected from different modalities [12]. 
Second, the parameter β is a regularization parameter that is used to balance the relative 
contributions of the two terms in Eq (5). Finally, it is worth noting that our objective 
function Eq (5) is formatted as a multi-task learning framework, where each imaging 
modality is used to predict the same response independently (i.e., Y1 = Y2 = ⋯ = Yn), but 
the feature selection is regularized jointly by the second term in Eq (5) to identify a set of 
consistent ROIs.
2.4. Diagnosis-Guided Multi-modality Phenotype Association
In this study, we try to develop a novel diagnosis-guided multi-modality (DGMM) 
framework to discover the multi-modality phenotypic associations with an AD genetic risk 
factor, where it explicitly models the priori diagnosis information among subjects in the 
objective function for selecting disease-relevant and robust multi-modality QTs associated 
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with the SNP. We induce the diagnosis label constraint into the multi-modality phenotypic 
solution and design a diagnosis-guided multi-modality (DGMM) phenotype association 
model as follows:
(6)
where  denotes a similarity matrix that measures the similarity between 
every pair of samples on the m-th modality across different subjects. Here, Lm = Dm − Sm 
represents a combinational Laplacian matrix for the m-th modality, where Dm is the 
diagonal matrix with element defined as . λ1 and λ2 denote control parameters 
of the regularization terms, respectively. Their values can be determined via inner cross-
validation on training data. It is promising to find the better solution that is robust to noises 
or outliers via considering both multimodalities and the rich information inherent in the 
observations. The objective function can be efficiently solved using the Nesterov's 
accelerated proximal gradient optimization algorithm which was used in [7], which is shown 
in the Algorithm 1.
Firstly, we separate the objective function into the smooth part Eq (7) and non-smooth part 
Eq (8) as following:
(7)
(8)
We define the approximation function Eq (9) as following, which is composited by the 
above smooth part and non-smooth one:
(9)
where  denotes the Frobenius norm, ∇f(Wi) denotes the gradient of f(W) on point Wi at 
the i-th iteration, and l is the step size. Then, the update step of Nesterov's APG is defined 
as:
(10)
where wj and vj denote the j-th row of the matrix W and V, respectively. NAGP performs a 
simple step of gradient descent to go from Wi to V, and then it slide a little bit further than
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(11)
Therefore, through Eq (9), this problem can be decomposed into d separate sub-problems. 
The key of APG algorithm is how to solve the update step efficiently. The analytical 
solutions of those sub-problems can be easily obtained:
(12)
Instead of performing gradient descent based on Wi, we compute the search point as:
(13)
where  and .
Algorithm 1: to minimize J in Equation (6)
3. Experiments
In this section, we evaluate the effectiveness of the proposed method on the ADNI-1 
database. For up-to-date data access information, see http://adni.loni.usc.edu/data-samples/
access-data/. One goal of ADNI is to test whether serial MRI, positron emission 
tomography, other biological markers, and clinical and neuropsychological assessment can 
be combined to measure the progression of mild cognitive impairment (MCI) and early AD. 
For more details, see www.adni-info.org. In our experiments, baseline structural MRI, FDG-
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PET scans, the top AD risk SNP APOE rs429358, another AD risk SNP CD33 rs386544 and 
non-risk SNP rs56283507 (for comparison purpose) are included. This yields a total of 357 
subjects, including 87 AD, 182 MCI and 88 HC participants. Table 1 shows the numbers for 
each diagnosis code and each SNP.
3.1. Imaging Phenotype Data
The SPM Statistical Parametric Mapping software package (SPM version 12, for more 
details, see www.fil.ion.ucl.ac.uk/spm/software/) was used to: (1) create normalized gray 
matter density maps from MRI data in the standard MNI space, and (2) register the FDG-
PET scans into the same space. The MarsBaR ROI toolbox [13] was used to extract mean 
gray matter density and FDG-PET glucose utilization values for each of 116 MarsBaR 
ROIs. These measures were pre-adjusted for age, gender, handedness and education.
3.2. Genotype Data
APOE (located on chromosome 19) has a key role in coordinating the mobilization and 
redistribution of cholesterol, phospholipids, and fatty acids, and it is implicated in 
mechanisms such as neuronal development, brain plasticity, and repair functions [14]. In 
imaging genetics research experiments, several whole-brain studies focused on mapping this 
risk genetic variable [10, 11]. In this work, we focused on studying the susceptibility SNP 
rs429358, which was determined using APOE ε2/ε3/ε4 status information from the ADNI 
clinical database for each participant. We also selected another AD risk SNP CD33 
rs386544 and a random non-risk SNP rs56283507 for the comparison purpose to evaluate 
the performance of the proposed model.
3.3. Experimental Settings
In our experiment, for the input of multimodal imaging phenotypes, we normalized the FDG 
and VBM whose ranges are -5.29 to 6.49 and -5.34 to 4.73, respectively. For the outcome, 
each SNP value is coded in an additive fashion as 0, 1 or 2, indicating the number of minor 
alleles. We have inserted this information in our revised manuscript. 5-fold cross-validation 
strategy was adopted to evaluate the effectiveness of our proposed method. As for 
parameters of regularization, we determined the values by nested 5-fold cross-validation on 
the training set. In current studies, we used SM (denoting single modality based method with 
Lasso [15] to detect a sparse significant subset from imaging phenotypic features (i.e., 
ROIs)), MC (denoting modalities concatenation with Lasso to detect a sparse subset from 
imaging phenotypes), MM (denoting multi-modality method to detect imaging phenotypes 
from a sparse subset of common ROIs), DGSM, DGMC and DGMM (the standard SM, MC 
and MM with DG, respectively, where DG denotes the diagnosis-guided strategy).
3.4. Results
We compare our proposed diagnosis-guided based methods (including DGSM, DGMC and 
DGMM) with conventional methods (including SM, MC and MM), respectively. The 
performance on each dataset is assessed with root mean squared error (RMSE) and 
correlation coefficient (CC) between actual and predicted response values, which are widely 
used in measuring performances of regression and association analysis. The average results 
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of RMSE and CC among the 5-fold test on MRI-VBM and FDG-PET modalities are 
calculated respectively as shown in Table 2 and Table 3. The corresponding values on the 
whole test data entirety (denoted Ent for short) are included in both tables, where predicted 
values from all cross-validation trials are pulled together for calculating a single RMSE or 
CC.
As shown in Table 2, the proposed DG based methods consistently outperform their non-DG 
based methods in the RMSE performance measure. This demonstrates that diagnosis-guided 
information can help improve regression performance from imaging phenotypes to 
genotype. DGMM and DGMC methods yield the best RMSE values of 0.9097 and 0.9096. 
Compared with the DG strategy, the joint regularization across multiple modalities showed 
negative effects on the RMSE performance in some cases (e.g., from SM to MM). 
Regarding the CC results in Table 3, our proposed method shows the best CC of 0.1499 with 
the MRI-VBM modality. The best CC of 0.1471 is obtained by DGMM in terms of the FDG 
measure while the second best performance is 0.1140 by our DGMM method. These results 
demonstrate the proposed methods can take advantage of consistent and robust 
multimodality information to find more important associations. Compared with the joint 
regularization across multiple modalities, the DG strategy had very limited contributions in 
most cases except the DGMM on MRI-VBM (compared with MM).
We also selected another AD risk SNP CD33 rs386544 and a random SNP rs56283507 as 
the comparison to evaluate the performance on the proposed model. As shown in Table 4, 
the DGMM method with APOE rs429358 yield the best RMSE and CC performance 
measures, which outperform the same method involved the CD33 rs386544 or the random 
SNP. This matches our expectation, since the APOE SNP has a larger effect size than the 
CD33 SNP and the random SNP. The originality of the work is to make full use of the risk 
genotype and corresponding disease samples to find the intermediate phenotype between an 
AD genetic marker and the disease status. For evaluation purpose, it is desired to select the 
top AD risk SNP to demonstrate our proposed model.
Besides the improved performances, one major goal of this study is to identify some 
significant and robust phenotypes that are highly correlated to risk genotype marker to 
capture imaging genetics associations in AD research.
The top 10 selected MRI-VBM imaging features, as well as their average regression 
coefficients on 5-fold test, are visualized in Fig. 1 by mapping them onto the human brain. 
The colors of the selected brain regions indicate the regression coefficients of the 
corresponding MRI-VBM markers. As expected, Hippocampus_Left, Hippocampus_Right 
and Amygdala_Left have been detected on top 10 ROIs associated with risk genotype 
biomarker by the proposed DGMM method. It's worth noting that these stable markers are in 
accordance with the existing findings. For example, the reduction of hippocampal gray 
matter has been correlated with APOE SNP rs429358 [16]. The APOE polymorphism is the 
best established genetic risk factor for pathological changes that is also associated with 
anatomical brain changes.
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The weights of the top 20 ROIs by every fold DGMM test on the heat map are plotted in 
Fig. 2. Our proposed method tends to select the stable ROIs such as Vermis_7, Vermis_10, 
Hippocampus_Left, Hippocampus_Right and Frontal_Inf_Oper_Left that span across five 
cross-validation trials. The APOE SNP is the best established genetic risk factor for 
pathological changes that is also associated with reductions of hippocampal gray matter and 
glucose metabolism [10, 16, 17]. It also demonstrates the robust and consistent ROIs should 
be selected among the independent and different modalities, which discovers the imaging 
genetic associations through biological interpretation. Although reduced volume of 
cerebellar vermis has been associated with dementia [18], the imaging genetic finding of 
Vermis_7 warrants further investigation.
4. Conclusion
In this study, we have developed a diagnosis-guided multi-modality (DGMM) framework 
for identifying neuroimaging phenotype associations with risk genetic biomarkers. This 
approach explicitly models the priori diagnosis information among subjects in the objective 
function for selecting the most relevant and robust multi-modality QTs (i.e., MRI-VBM and 
FDG-PET) associated with top risk SNP (i.e., APOE rs429358). Experimental results on the 
ADNI database showed that our proposed DGMM method not only achieved better 
prediction performances under the metrics of correlation coefficient and root mean squared 
error compared with other single modality and non-diagnosis-guided methods, but also 
detected a compact set of robust and consistent ROIs across the multimodal phenotypes 
among the populations to guide the disease-induced biological interpretation. The similar 
model can be also extended to the investigation of association analyses between multi-modal 
brain imaging measures and any other biomarkers such as those in cerebrospinal fluid. 
Furthermore, the DGMM framework can be applied to other genetic associated diseases to 
investigate the complex biological mechanisms from genetics to intermediate traits to 
diagnostic outcome. An interesting future direction is to improve the efficiency of our 
implementation and apply it to larger scale studies such as analyzing high dimensional voxel 
based imaging data as well as a comprehensive set of genetic risk factors.
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Fig. 1. 
Visualization of the top 10 VBM ROIs selected by the proposed method.
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Fig. 2. 
Heat map of the top VBM and FDG ROI associations with APOE SNP rs429358 learned by 
the proposed method.
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Table 2
Comparison of regression performances of the competing methods in terms of Root Mean 
Square Error (RMSE)
Method
MRI-VBM FDG-PET
(Mean ± Std) 5-fold Ent (Mean ± Std) 5-fold Ent
SM 1.0103±0.1123 1.0185 0.9538±0.0549 0.9569
DGSM 0.9097±0.0342 0.9107 0.9205±0.0446 0.9225
MC 0.9547±0.1088 0.9635 0.9127±0.0364 0.9138
DGMC 0.9096±0.0342 0.9635 0.9096±0.0342 0.9106
MM 1.3358±0.1081 1.3417 1.2267±0.0400 1.2280
DGMM 0.9097±0.0342 0.9107 0.9097±0.0342 0.9106
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Table 3
Comparison of regression performances of the competing methods in terms of 
Correlation Coefficient (CC)
Method
MRI-VBM FDG-PET
(Mean ± Std) 5-fold Ent (Mean ± Std) 5-fold Ent
SM -0.0154±0.1015 -0.0997 -0.1307±0.1323 -0.0557
DGSM 0.0090±0.1326 0.0039 -0.0322±0.0857 0.0363
MC -0.0913± 0.1609 0.0345 0.0164±0.0605 -0.1037
DGMC -0.0241±0.1318 -0.0650 -0.0354±0.1251 0.0525
MM 0.0928±0.0796 0.0886 0.1471±0.0804 0.1492
DGMM 0.1499±0.0384 0.1465 0.1140±0.0780 0.1002
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Table 4
Comparison performances (RMSEs and CCs) in our proposed model with top risk SNP APOE rs429358, 
another risk SNP CD33 rs386544, and a random non-risk SNP rs56283507.
Candidate SNPs
MRI-VBM FDG-PET
RMSE CC RMSE CC
APOE-rs429358 0.9097±0.0342 0.1499±0.0384 0.9097±0.0342 0.1140±0.0780
CD33-rs386544 0.9123±0.0779 0.0582±0.1134 0.9123±0.0779 0.0960±0.0823
rs56283507 0.9628±0.0346 0.0677±0.1495 0.9628±0.0346 0.0125±0.0686
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